DirectHit is a diagnostic test panel developed by CCC Diagnostics to predict patient response to breast cancer treatments. It analyzes multiple biomarkers from tissue samples using quantitative immunofluorescence to determine effectiveness of hormonal therapies, targeted drugs like Trastuzumab, and chemotherapy drugs. DirectHit aims to personalize treatment selection by identifying ineffective treatments upfront, improving outcomes and reducing costs compared to standard testing methods. CCC Diagnostics is currently expanding DirectHit to additional cancers and chemotherapy drugs based on promising early results.